Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome.
Tue, 07/03/2017 - 16:45
0 min
Download related document
Select rating
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 1/5
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 2/5
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 3/5
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 4/5
Give The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. 5/5
No votes yet
Related
First three months 2024 results press release
Operating revenue was 151.2 million euros in the first quarter of 2024, a 25% decrease on the first quarter of 2023, mainly due...
4 min
08/05/2024
ROVI announces agreement to manufacture pre-filled syringes
Agreement to manufacture pre-filled syringes for a global pharmaceutical company Production will take place on one state-of-the-art...
3 min
25/04/2024
ROVI receives the FDA’s approval of Risvan® as a treatment for schizophrenia
Madrid – 2 April, 2024 – Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the U.S. Food and Drug...
4 min
02/04/2024
See More
Email
Facebook
Twitter
LinkedIn